Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Apricus Biosciences, Inc. (APRI - Snapshot Report) reported second-quarter 2013 loss of 15 cents per share, narrower than the year-ago loss of 16 cents. Second-quarter loss was wider than the Zacks Consensus Estimate of a loss of 13 cents.

Revenues increased to $1.2 million from $0.3 million in the year-ago quarter. The increase was due to a $0.6 million increase in license fee revenue, which comprised a $0.3 million milestone payment from Bracco SpA and deferred revenues of $0.3 million. The increase in revenue was also due to a $0.6 million increase in contract service revenue.

Research and development (R&D) expenses increased 49% to $1.5 million. Expenses were driven by increased consulting services in support of Biodel’s regulatory filings in Europe and higher expenses associated with the manufacture and regulatory filings for Vitaros. General and administrative expenses increased 12% to $3.7 million in the reported quarter.

Vitaros (erectile dysfunction) is the only approved product of Apricus. In Jun 2013, Apricus received approval for Vitaros under the European Decentralized Procedure (DCP). Apricus’ marketing approval application for Vitaros designated Netherlands as the Reference Member State (RMS) on behalf of nine other European Concerned Member States (France, Germany, Italy, UK, Ireland, Spain, Sweden, Belgium and Luxembourg) that participated in the procedure.

Recently, Apricus got national phase approvals for Vitaros in Ireland, The Netherlands, the UK and Sweden.

The company’s main area of focus for 2013 is the launch of Vitaros and clinical development of Femprox (female sexual dysfunction treatment). Vitaros and Femprox are both based on Apricus’ proprietary drug delivery technology, NexACT.

Currently Apricus carries a Zacks Rank #3 (Hold). Companies which look attractive include Gilead Sciences Inc. (GILD - Analyst Report), Biogen Idec Inc. (BIIB - Analyst Report) and Actelion Ltd. (ALIOF) with a Zacks Rank #1 (Strong Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%